Siemens filed the initial mdr 1219913-2019-00146 on august 1, 2019.08/07/2019 additional information: patient treatment was not prescribed or altered.The type of blood collection tube that was used was serum, bd vaccutainer.Siemens is awaiting further information from the customer.
|
Siemens filed the initial mdr 1219913-2019-00146 on (b)(6) 2019.Siemens filed the mdr 1219913-2019-00146 supplemental report 1 on (b)(6) 2019.(b)(6)2019 additional information: siemens has requested the advia centaur xp ahbs2 lot number that was used to test the sample at the pathlab singapore from the customer.The response received was no lot information was provided.(b)(6)2019 additional information: the customer had a sample that recovered repeat reactive (22.64, 21.23 miu/ml) with advia centaur cp anti-hbs2 (ahbs2) lot 102 but was nonreactive when tested with an advia centaur xp at another lab.The sample was hbsag reactive at the customer's lab and the other lab.They believe the nonreactive ahbs2 result.The customer was not able to provide the patient's medical status or a list of medications/supplements the patient is taking.There is no sample that can be sent to siemens for evaluation.The relative sensitivity and specificity section of the advia centaur cp anti-hbs2 instructions for use (ifu) (10629924, revision j, 2017-12) lists the 95% confidence interval (ci) for resolved relative specificity as 98.34% - 99.88% so a certain number of false positive results can be expected for this assay.This one false positive result does not indicate a product problem with advia centaur cp ahbs2 lot 102.The cause of the false positive results seen by the customer with this one sample when using advia centaur cp ahbs2 lot 102 could not be determined but siemens cannot rule out pre-analytical factors, a sample issue, or normal assay performance.Based on the investigation, no product problem was identified.The instrument is performing within specifications.No further evaluation of the device is required.
|